Ampullary Adenoma, Chemotherapy Effect
Conditions
Brief summary
Ampullary cancer, a rare malignancy, lacks standardized guidelines for effective multimodal treatment following curative resection. The opinions on whether postoperative chemotherapy can improve the long-term survival of ampullary adenocarcinoma (AA) are discordant. This aspect remains poorly studied, with comparably scant research conducted on it. log odds of positive lymph nodes (LODDS), a quantitative variable, can continuously and accurately reflect the burden of nodal involvement, which suggested a potential ability to identify AA patients benefiting from postoperative adjuvant chemotherapy (ACT). Therefore, Mainly focused issues of ACT addressed in the study are as follows: 1) the role of ACT in improving long-term survival for patients with AA after curative resection. 2) the role of LODDS in identifying postoperative AA patients benefiting from ACT. 3) compared with T and N classifications reported previously, the advantage of LODDS in identifying ACT-benefited patients. In this cohort study, a large scale of sample size was conducted by drawing on the collective experience of the National Cancer Center of China. The patients treated with radiotherapy were excluded to concentrate on the effect of ACT.
Interventions
DRUGAdjuvant chemotherapy
In the Cancer Hospital, postoperative chemotherapy regimens and doses were planned by oncologists, with adjustments made based on drug toxicities or tumor responses.
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Inclusion criteria
Pathologically confirmed AA patients without distant metastasis treated with curative-intent resection
Exclusion criteria
patients who received neoadjuvant therapy or radiotherapy, as well as those with missing clinical pathological or follow-up information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The role of adjuvant chemotherapy(ACT) | 1 year | The association between ACT and Overall Survival (OS) of patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The role of adjuvant chemotherapy(ACT) | 1 year | The association between ACT and Cancer-specific Survival (CSS) of patients |
Countries
China
Outcome results
None listed